Our results suggest that besides the evaluation of PD‐L1 expression by tumor biopsy, the differential expression of PD‐L1 and Ki67 on CTCs could provide further predictive information for NSCLC patients treated with ICIs. This evidence concerns the gene MKI67 and neoplasm.